Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Morphosys triples Q1 loss as new subsidiary ramps up costs

Published 04/05/2022, 21:01
Updated 04/05/2022, 21:05
© Reuters.

FRANKFURT (Reuters) - German drugmaker Morphosys reported a three-fold increase in its quarterly net loss on Wednesday due to higher costs after the acquisition of U.S. cancer specialist Constellation Pharmaceuticals.

The group said its net loss tripled to 122.7 million euros ($129.19 million) in the first quarter of 2022 from 41.6 million euros last year due to new research and development expenses and financing-related payments after its Constellation acquisition.

Morphosys bought the rival in July to expand its pipeline with advanced experimental cancer drugs, which are expensive to research, and is paying royalties under a deal it had struck with investor Royalty Pharma to pay for the acquisition.

The drugmaker confirmed the 2022 financial targets it published in January and reiterated in March as well as May.

($1 = 0.9498 euros)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.